All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @adrian.cuellar.derma on TikTok · 90s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @adrian.cuellar.derma's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:10I'm not sure this is the first time I've ever seen.
  2. 0:13This is a very simple, simple perfect theme of the game.
  3. 0:16I've already seen the theme of the game,
  4. 0:18which is the most important theme of the game.
  5. 0:20Because I'm not sure that the game is a very important theme.
  6. 0:23I know that it is the most interesting thing that I've ever seen in the game.
  7. 0:28I'm not sure that the game is a very simple theme.
  8. 0:31I think it is a very important theme,
  9. 0:34and that is what the game is.
  10. 0:36After the war, I am familiar with the fact that I live in New York and I am learning from
  11. 0:41the other parts of the country.
  12. 0:42I am learning about the origin of the country, and I am learning about the origin of the
  13. 0:48country, and I'm learning about the origin of the country.
  14. 0:50I am learning about the speaking of our fellow languages and the origin of the people, the
  15. 0:54origin of the country, and the culture.
  16. 0:57I do see a lot of links on the part where I live in the language, the story tells a lot
  17. 1:02of the stories.
  18. 1:03Later, in the digital, writing, writing, and that.
  19. 1:07You should drive to the other side.
  20. 1:08But I also talk to The
  21. 1:26Cha do you like it?
  22. 1:27It is cool.

Does Ozempic really cause 'Ozempic face'? We checked

DermAdrian

TikTok creator

20.0K viewsWatch on TikTok

Quick answer

GLP-1 receptor agonists such as semaglutide and tirzepatide produce significant total body weight loss that can include facial fat pad volume reduction, contributing to the colloquially termed 'Ozempic Face.' Poly-L-lactic acid biostimulators like Sculptra have peer-reviewed evidence supporting collagen neogenesis and gradual volume restoration, but their appropriateness depends on patient stability, weight loss trajectory, and individualized assessment by a licensed provider. No cosmetic intervention has been studied in randomized controlled trials specifically for GLP-1-associated facial changes as of the most recent literature.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Does Ozempic really cause 'Ozempic face'? We checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Does Ozempic really cause 'Ozempic face'? We checked" from DermAdrian. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists such as semaglutide and tirzepatide produce significant total body weight loss that can include facial fat pad volume reduction, contributing to the colloquially termed 'Ozempic Face.

The reason this review is not generic is the source wording and the canonical claim label "glp1 has escuchado de la ozempic face cuando la p rdida de pe." In this clip, the useful excerpt is: "I'm not sure this is the first time I've ever seen." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The STEP-1 trial (Wilding et al.
People who land here are usually trying to understand whether the Compounded Semaglutide claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists such as semaglutide and tirzepatide produce significant total body weight loss that can include facial fat pad volume reduction, contributing to the colloquially termed 'Ozempic Face.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists such as semaglutide and tirzepatide produce significant total body weight loss that can include facial fat pad volume reduction, contributing to the colloquially termed 'Ozempic Face.' Poly-L-lactic acid biostimulators like Sculptra have peer-reviewed evidence supporting collagen neogenesis and gradual volume restoration, but their appropriateness depends on patient stability, weight loss trajectory, and individualized assessment by a licensed provider. No cosmetic intervention has been studied in randomized controlled trials specifically for GLP-1-associated facial changes as of the most recent literature.
  • Akhavan et al. (2023, JAMA Dermatology) confirmed GLP-1-associated facial aging is a real clinical phenomenon, not a social media myth.
  • The STEP-1 trial (Wilding et al., 2021, NEJM) showed average 14.9 percent body weight reduction with semaglutide, a magnitude sufficient to alter facial fat distribution.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • Akhavan et al. (2023, JAMA Dermatology) confirmed GLP-1-associated facial aging is a real clinical phenomenon, not a social media myth.
  • The STEP-1 trial (Wilding et al., 2021, NEJM) showed average 14.9 percent body weight reduction with semaglutide, a magnitude sufficient to alter facial fat distribution.
  • Sculptra (poly-L-lactic acid) has peer-reviewed evidence for collagen stimulation, but requires 2 to 3 treatment sessions over months and does not directly replace lost fat pads.
  • Most experienced injectors recommend waiting until body weight stabilizes before pursuing facial volume restoration, since ongoing loss changes the treatment target.
  • Skin laxity, a separate component of facial aging during weight loss, is not addressed by Sculptra and may require different interventions such as radiofrequency or surgical tightening.
  • No randomized controlled trial has evaluated Sculptra or any biostimulator specifically for GLP-1-related facial changes as of current published literature.
  • Patients should consult a board-certified dermatologist or plastic surgeon familiar with weight-loss patients before pursuing any cosmetic procedure during or after GLP-1 therapy.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @adrian.cuellar.derma actually say?

The transcript provided is garbled and appears to be a mistranslation or transcription error, so the actual spoken content can't be directly quoted. Based on the video caption, the creator claims that rapid weight loss from GLP-1 medications causes facial fat loss, producing a "more sunken, tired, or aged" appearance, and that biostimulators like Sculptra can solve this problem.

That's a two-part claim: first, that GLP-1-related rapid weight loss depletes facial fat specifically; second, that Sculptra is an effective corrective treatment. Both claims are worth examining separately because they carry different levels of evidence behind them.

The creator appears to be a dermatology-focused account, and the framing is promotional in tone. That's worth keeping in mind as you read on.

Does the science back this up?

The "Ozempic Face" phenomenon is real, but the mechanism is more complex than the caption implies. Yes, the evidence supports facial volume loss during significant weight reduction on GLP-1 agonists.

A 2023 commentary in JAMA Dermatology (Akhavan et al., 2023) directly addressed GLP-1-associated facial aging, noting that rapid fat redistribution and collagen changes contribute to a gaunt appearance. The issue is not limited to facial fat alone. Skin laxity, reduced subcutaneous support, and changes in dermal collagen all play roles. Sculptra, containing poly-L-lactic acid (PLLA), does have evidence for stimulating collagen production and restoring volume. Vleggaar (2006, Journal of the European Academy of Dermatology and Venereology) and subsequent studies confirmed PLLA's biostimulatory effects over 3 to 6 months. However, calling this a straightforward "solution" overstates the evidence. Sculptra addresses collagen loss, not necessarily fat pad restoration, and patient selection, injection technique, and realistic expectations all matter enormously.

What did they get wrong (or right)?

Credit where it's due: the core observation is accurate. GLP-1 receptor agonists like semaglutide and tirzepatide do cause weight loss that can affect facial appearance. The 2021 STEP-1 trial (Wilding et al., New England Journal of Medicine) showed average body weight reductions of nearly 15 percent with semaglutide, and facial fat is not exempt from that process.

Where the caption oversimplifies: facial fat loss during GLP-1 use is not purely a speed problem. The degree of total weight loss matters more than pace alone. Blaming "very rapid" weight loss as the primary driver can mislead patients into thinking slower weight loss fully protects their face. It often doesn't at the same weight loss magnitude.

The "sí tiene solución" framing, meaning "yes, it has a solution," is also reductive. Sculptra is one option. It's not appropriate for every patient, it requires multiple sessions, and it doesn't address skin laxity. Presenting it as the answer without those caveats is the kind of oversell that erodes patient trust when results are modest.

What should you actually know?

If you're on a GLP-1 medication and noticing changes in your face, here's what the evidence actually says.

  • Facial volume loss is a real and documented side effect of significant weight reduction, not a marketing invention.
  • Biostimulators like Sculptra have legitimate clinical backing, but they work gradually, typically requiring two to three treatment sessions over several months before full results appear.
  • Sculptra is not the only option. Hyaluronic acid fillers, fat grafting, and skin-tightening procedures each have different evidence profiles and suit different presentations.
  • The decision to pursue any cosmetic procedure during active GLP-1 treatment should involve a dermatologist or plastic surgeon experienced with weight-loss patients, since body composition continues changing.
  • Nothing in the peer-reviewed literature supports rushing into facial procedures while still actively losing weight. Most specialists recommend stabilizing weight first.

This content is educational only. Any cosmetic or medical decision should be made with a licensed provider who knows your full health history.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

DermAdrian · TikTok creator

20.0K views on this video

¿Has escuchado de la “Ozempic Face”? Cuando la pérdida de peso es muy rápida, también se pueden perder las grasitas naturales del rostro, haciendo que la cara se vea más hundida, cansada o envejecida.

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about akhavan et al. (2023, jama dermatology) confirmed glp-1-associated facial aging?

Akhavan et al. (2023, JAMA Dermatology) confirmed GLP-1-associated facial aging is a real clinical phenomenon, not a social media myth.

What does the video say about the step-1 trial (wilding et al., 2021, nejm) showed average?

The STEP-1 trial (Wilding et al., 2021, NEJM) showed average 14.9 percent body weight reduction with semaglutide, a magnitude sufficient to alter facial fat distribution.

What does the video say about sculptra (poly-l-lactic acid) has peer-reviewed evidence for collagen stimulation,?

Sculptra (poly-L-lactic acid) has peer-reviewed evidence for collagen stimulation, but requires 2 to 3 treatment sessions over months and does not directly replace lost fat pads.

What does the video say about most experienced injectors recommend waiting until body weight stabilizes before?

Most experienced injectors recommend waiting until body weight stabilizes before pursuing facial volume restoration, since ongoing loss changes the treatment target.

What does the video say about skin laxity, a separate component of facial aging during weight?

Skin laxity, a separate component of facial aging during weight loss, is not addressed by Sculptra and may require different interventions such as radiofrequency or surgical tightening.

What does the video say about no randomized controlled trial has evaluated sculptra?

No randomized controlled trial has evaluated Sculptra or any biostimulator specifically for GLP-1-related facial changes as of current published literature.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by DermAdrian, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.